个人简介
ACADEMIC DEGREES
1990 PhD, University of Sydney
1985 BSc (Hons) (Biochemistry), University of NSW
ACADEMIC AND RESEARCH APPOINTMENTS
2015 - Professor, School of Biological Sciences, University of Wollongong
2014 - Illawarra Lead and CI CONCERT Translational Cancer Research Centre
2013 – Visiting Research Fellow, Institute of Genetics and Biophysics, National Research Council, Naples Italy
2009 - 2012 Scientific Director, Cancer Continuum, Illawarra Health and Medical Research Institute
2009 – Visiting Research Fellow, Finsen Laboratory, University of Copenhagen, Denmark
2006- Associate Professor, School of Biological Sciences, University of Wollongong
2005-2008 - Cancer Institute NSW Fellow (based at University of Wollongong)
2004 - Gessellschaft fur Biotechnologische Forschung (GBF) Fellow, Braunschweig, Germany
1998-2005 - Lecturer/Senior Lecturer, Department of Biological Sciences, University of Wollongong
1993-1997 - Research Fellow, Department Biological Sciences, University of Wollongong
1990-1992 - Fogarty Visiting Post-Doctoral Fellow, National Institutes of Health, Bethesda USA
研究领域
Prof Ranson has an ongoing research interest in the cell and molecular biology of cancer migration, invasion and metastasis with a particular focus on the urokinase plasminogen activation system (PAS) and the putative protective role of its inhibitor SerpinB2 (PAI-2) in cancer. She also leads the pre-clinical development of targeted anti-cancer drugs, as well as improved delivery of chemotherapeutic drugs. Prof Ranson also contributes to research regarding streptococcal pathogenesis.
近期论文
查看导师新发文章
(温馨提示:请注意重名现象,建议点开原文通过作者单位确认)
Lee JA, Yerbury JJ, Farrawell N, Shearer RF, Constantinescu P, Hatters DM, Schroder WA , Suhrbier A, Wilson MR, Saunders DN, Ranson M. (2015) SerpinB2 (PAI-2) Modulates Proteostasis via Binding Misfolded Proteins and Promotion of Cytoprotective Inclusion Formation. PLoS ONE 10(6): e0130136.doi:10.1371/journal.pone.0130136.
Vine KL, Lobov S, Chandran VI, Harris NLE and Ranson M. (2015) Improved Pharmacokinetic and Biodistribution Properties of the Selective Urokinase Inhibitor PAI-2 (SerpinB2) by Site-Specific PEGylation: Implications for Drug Delivery. Pharmaceutical Research, 32:1045-1054
Sanderson-Smith ML, Zhang Y, Ly D, Donahue D, Hollands A, Nizet V, Ranson M, Ploplis VA, Walker MJ, Castellino FJ. (2013) A Key Role for the Urokinase Plasminogen Activator (uPA) in Invasive Group A Streptococcal Infection. PLOS Pathogens. 9(7): e1003469. doi:10.1371/journal.ppat.1003469.
Vine KL Chandran VI, Locke JM, Matesic L, Lee J, Skropeta D, Bremner JB and Ranson M. (2012) Targeting Urokinase and the Transferrin Receptor with Novel, Anti-Mitotic N-Alkylisatin Cytotoxin Conjugates Causes Selective Cancer Cell Death and Reduces Tumor Growth. Current Cancer Drug Targets. 12:64-73
Cochran BJ, Croucher DR, Lobov, S, Saunders DN and Ranson M. (2011) Dependence on endocytic receptor binding via a minimal binding motif underlies the differential prognostic profiles of serpinE1 and serpinB2 in cancer. Journal of Biological Chemistry. 286: 24467-24475.
Matthews H, Ranson M and Kelso MJ. (2011) Anti-Tumour/Metastasis Effects of the Potassium-Sparing Diuretic Amiloride: An Orally Active Anti-Cancer Drug Waiting for its Call-of-Duty? International Journal of Cancer. 129, 2051–2061.
Vine KL, Matesic L Locke JM, Ranson M and Skropeta D. Cytotoxic and Anticancer Activities of Isatin and its Derivatives: A Comprehensive Review from 2000-2008. (2009) Anticancer Agents in Medicinal Chemistry.9:397-414
Croucher DR, Saunders DN, Lobov S and Ranson M. (2008) Revisiting the biological roles of PAI2 (SERPINB2) in cancer. Nature Reviews Cancer. 8:535-545.
Stutchbury TK, Al-ejeh F, Stillfried GE, Croucher DR, Andrews JA, Irving D, Links M and Ranson M. (2007) Preclinical evaluation of PAI-2-DTTA-213Bi (alpha-PAI-2) in an orthotopic murine xenogenic model of human breast carcinoma. Molecular Cancer Therapeutics. 6: 203-212.